BioNTech Completes Phase II Trial of COVID-19 Vaccine in China

May 10, 2022

(Reuters) – Vaccine developer BioNTech completed a Phase II clinical trial of its COVID-19 vaccine in China in January but has yet to release its results, a registry of such trials showed on Tuesday. The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive approval in China, which has vaccinated 89% of its 1.4 billion population with several domestically developed non-mRNA shots. (Read More)